For MS, migraine, epilepsy, and other neurological conditions, treatment options have expanded in ways that would have seemed impossible a decade ago. Yet many of those treatments never turn into started therapies because of specialty medication barriers.
During Multiple Sclerosis (MS) Awareness Month, it’s worth pausing on a difficult truth: Between prior authorization requirements, benefits confusion, specialty pharmacy coordination, and financial questions, patients are left in the dark at moments when clarity matters most. Meanwhile, providers take on considerable operational strain. That reality is reshaping how neurologists practice—and how much capacity they have to support the patients they treat.
The Weight Neurologists Carry When Prescribing Specialty Medications
Fifty percent of physicians treating patients with MS reported feeling burned out or beginning to experience burnout, according to a 2024 survey published in Neurology and Therapy. EHR-related stress and long work hours were the leading drivers, and nearly half of respondents had considered leaving the field.
For neurologists treating MS, the burden goes beyond administrative tasks. They manage a progressive, unpredictable disease where treatment timing matters. When access delays stand between a patient and a prescribed therapy, the frustration hits at professional and personal levels.
Inefficient prior authorization (PA) processes are a major contributor. Staff at MS practices spend an estimated 20–30 hours per month navigating insurance coverage restrictions, and 88% of surveyed physicians rated the PA burden as “high or extremely high,” notes research published in the International Journal of MS Care.
In addition, PA processes can be more complex with MS care. For example, oral and self-injectable disease-modifying therapies typically fall under pharmacy benefits. However, infused therapies—often used as high-efficacy, first-line treatments—may fall under medical or both benefit types. Each benefit channel has its own PA process, payer criteria, and timeline, increasing the burden on already overworked clinicians and staff.
When providers spend this much time navigating paperwork—even if it is digital—it means less time and energy to guide patients through cost or therapy concerns.
Specialty Medication Barriers From the Patient Perspective
A substantial number of specialty prescriptions are never filled—not because patients aren’t motivated, but because of gaps at critical moments in their therapy journey.
Time-to-therapy was meaningfully longer when PA was needed versus when it was not, according to the International Journal of MS Care study noted above. When delays are measured in weeks (or months) rather than days, the consequences for patients diagnosed with MS can be devastating. And it’s not only MS specialty therapies that are affected. A July 2025 KFF Health Tracking Poll found that among insured adults, more than half experienced a delay or denial tied to prior authorization for a prescribed therapy or procedure. Many reported difficulties navigating the process, and financial uncertainty led some to forgo care altogether.
That’s why well-timed prescription engagement is so important.
Patients leave the provider’s office ready to start therapy. But too often, days pass without any updates on PA status, specialty pharmacy next steps, or early connection to copay or hub resources. By the time a patient support program reaches them, confusion may have already set in.
The Case for Upstream Engagement
The prescribing moment is the most influential stage for ensuring treatment success. Provider attention is focused. Patient motivation is high. And the right information—copay support, PA resources, hub enrollment guidance, clear next steps—can prevent abandonment instead of chasing failures-to-fill down the line.
Unfortunately, most patient support programs operate downstream. They engage patients after friction has already disrupted momentum.
TimelySM by DrFirst® addresses that gap by embedding friction-free, prescribing decision support directly into the EHR workflow with no separate portal, and no workflow disruption. Brand-specific content reaches providers directly within the EHR, such as:
- Alerting providers when a prescription requires a specialty or limited-distribution pharmacy. If a medication can’t be dispensed at a retail pharmacy, it’s flagged within the EHR prescribing workflow, giving the provider what they need to route the script correctly with one click before the patient leaves the office.
- Identifying a relevant diagnosis code before the prescription is sent. When an ICD-10 code is needed to support PA submission or to qualify a patient for a PA exemption, Timely surfaces that gap in real time, reducing downstream denials caused by documentation errors.
- Producing cleaner scripts from the start. Powered by the DrFirst medication management infrastructure, prescriptions are written so they meet pharmacy dispensing needs consistently, eliminating phone tag between providers and pharmacists and getting patients on therapy faster.
- Supporting meaningful conversations about affordability before the patient visit ends. Prescribers get price transparency based on a patient’s actual benefits, so they can discuss cost concerns and support options like copay cards.
Then, within minutes of the prescription being sent to the pharmacy, patients receive an automated, personalized text from their trusted provider. That distinction matters. Engagement rates through provider-facilitated outreach reach up to 88% with Timely, compared to typical industry rates of 15–20% for direct-to-patient approaches.
In MS treatment, where patients may face separate pharmacy and medical benefit PA processes depending on therapy type, early guidance is especially important. Upstream engagement means patients receive support before they encounter their first barrier—not after they have already disengaged.
Proven Results That Break Down Specialty Medication Barriers
As one director of patient support programs at a Top 20 pharma brand shared:
“Timely helped us reach patients at just the right moment with the resources they needed to access their therapy—without adding any lift to our internal team.”
Improving specialty therapy access is often framed as a patient outcome issue. It is also a provider experience issue. When brands reduce friction at the point of prescribing, the benefits extend across the system:
- Prescribers gain back time and focus.
- Care teams field fewer reactive calls.
- Patients move from prescription to therapy with clearer guidance and less uncertainty, improving first-fills, ongoing adherence, and health outcomes.
For MS and other complex neurologic conditions, this shift can positively impact providers and patients.
If you’re rethinking how your brand supports specialty therapy access, now is the time to examine what happens at critical moments between prescribing and adherence. Let’s talk!
